Biologics Data Protection In Trade Agreements Becoming Key Focus For PhRMA
This article was originally published in The Pink Sheet Daily
Executive Summary
At a House hearing PhRMA representative cites the need for 12 years test data exclusivity for biologics in the Trans-Pacific Partnership Agreement. Separately, USTR issues its 2012 Special 301 Report.
You may also be interested in...
Biologics Exclusivity: GPhA Making Last Stand Against TPP
The U.S. Generic Pharmaceutical Association and other groups are opposing the Trans-Pacific Partnership requirement that biologics receive 12 years of exclusivity in part because they don’t want Congress to be unable to change it later.
Biologics Exclusivity: GPhA Making Last Stand In Pacific
GPhA, AARP oppose Trans-Pacific Partnership requirement that biologics receive 12 years of exclusivity in part because they don’t want Congress to be unable to change it later.
Asian Free Trade Deal Could Strengthen Canadian Patent Rights, PhRMA Says
Brand industry hopes weaknesses in Canada’s intellectual property regime, including lack of patent term restoration and a higher patent utility standard for biopharmaceutical products, could be addressed through the 11-nation talks on a Trans-Pacific Partnership agreement.